India Vials Market, By Preparation (Ready to use (RTU), Ready to sterilize (RTS)), By Application (Small molecules, Biologics, Diagnostics), By Material (Glass, Polymer, Hybrid), By End User (Hospitals & clinics, Pharma & biotech companies, Contract development and manufacturing organizations (CDMOs), Diagnostic laboratories, Other), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Vials Market was valued at USD 655.76 Million in 2024 and is expected to grow to USD 860.90 Million by 2030 with a CAGR of 4.60% during the forecast period.

The India vials market plays a critical role in the country’s pharmaceutical packaging sector, focused on the production and distribution of vials for storing and administering injectable medications. This market has seen robust growth, fueled by the increasing demand for injectable therapeutics, the expanding pharmaceutical industry, and ongoing advancements in packaging technologies.

Manufacturers are required to comply with stringent regulations, including the standards outlined by the Central Drugs Standard Control Organization (CDSCO) and Good Manufacturing Practices (GMP), ensuring the quality and safety of products. As the demand for injectable drugs rises, particularly due to the growing prevalence of chronic diseases, and as innovations in packaging technologies continue to emerge, the market is positioned for further expansion. To capitalize on this growth, stakeholders must prioritize strategic investments in production capabilities while maintaining strict adherence to regulatory frameworks to remain competitive and ensure compliance.

Key Market Drivers

Expansion of the Pharmaceutical Industry

The expansion of India’s pharmaceutical industry is a key driver of the Indian vials market, as rising production of injectable drugs, biologics, and vaccines increases the need for reliable packaging solutions. Growing cases of chronic diseases such as cancer, diabetes, and autoimmune disorders have boosted demand for injectable treatments that require vials for safe storage and delivery.

India’s expanding middle class around 41% of the 1.4 billion population along with increasing health insurance coverage has improved access to medicines, further supporting pharmaceutical production. The country is also focusing on strengthening domestic API manufacturing to reduce its current 70% import dependency, mainly from China. At the same time, the rapid growth of biopharmaceuticals, including monoclonal antibodies, gene therapies, and biosimilars, requires specialized vials that meet strict regulatory standards.

India’s strong position in global vaccine production and expanding immunization programs continue to drive large-scale demand for vaccine vials. Additionally, the country’s leadership in generic drug manufacturing and increasing pharmaceutical exports to markets such as the U.S. and Europe require high-quality vials compliant with international regulations. The shift toward patient-centric healthcare, including self-administered injectable therapies and pre-filled vials for single-dose use, is further contributing to the growing demand for specialized vial packaging solutions.

Download Free Sample Report

Surge in Demand for Injectable Drugs

The surge in demand for injectable drugs is a major factor driving the growth of the Indian vials market, as treatments for chronic diseases, infections, and cancers increasingly rely on injectable therapies that require safe and sterile packaging. The rising burden of conditions such as diabetes affecting about 77 million adults in India with another 25 million prediabetic along with cardiovascular diseases, cancer, and autoimmune disorders has significantly increased the need for injectables like insulin, monoclonal antibodies, and biologics.

India also has around 1.1 million people who inject drugs, with an HIV prevalence of about 10%, highlighting additional healthcare needs. The growing development of biologics, biosimilars, and advanced biopharmaceutical therapies including monoclonal antibodies and gene therapies further strengthens demand for specialized vial packaging that ensures product stability and sterility. India’s strong role in global vaccine production and expanding immunization programs have also accelerated the need for vaccine vials.

In addition, the biopharmaceutical sector, which contributed about USD 39.4 billion to India’s bioeconomy in 2021, continues to expand, increasing the requirement for temperature-sensitive and high-quality vial packaging. The shift toward patient-centric care, including home-based treatment and self-administration through pre-filled injectables, along with supportive government regulations and CDSCO guidelines for high-quality injectable manufacturing, is further boosting the demand for advanced vial packaging solutions in India..

Increase in Vaccination Programs and Biologics

The increase in vaccination programs and the rapid expansion of biologics are key drivers of the Indian vials market, as vaccines and biologic therapies require reliable injectable packaging. India is one of the world’s largest vaccine producers, supplying vaccines for diseases such as polio, tuberculosis, hepatitis, and COVID-19, which has significantly increased the demand for vials used in storage and distribution.

Government immunization initiatives, including the Universal Immunization Program (UIP), vaccinate around 26 million newborns and 30 million pregnant women annually through over 9 million sessions supported by nearly 27,000 cold-chain points, further boosting vial consumption. India has also administered more than 2.2 billion COVID-19 vaccine doses, highlighting the scale of vaccine demand. At the same time, the growing adoption of biologics such as monoclonal antibodies, gene therapies, recombinant proteins, and advanced vaccines has increased the need for specialized vials that ensure sterility, stability, and temperature control.

India’s strong role as a global vaccine supplier and the rising demand for biologics in areas like oncology and autoimmune diseases are accelerating vial demand for both domestic use and exports. Additionally, innovations such as pre-filled vials and syringes, along with strict regulatory standards from organizations like CDSCO, WHO, and the U.S. FDA, are encouraging the development of high-quality vial packaging, further supporting market growth.

Key Market Challenges

Stringent Regulatory Compliance and Quality Standards

The Indian vials market operates in a highly regulated environment, where manufacturers must comply with rigorous standards and quality controls to ensure the safety, efficacy, and integrity of pharmaceutical products. Regulatory bodies such as the Central Drugs Standard Control Organization (CDSCO) impose strict requirements on packaging materials and processes, including vials used for injectable drugs, vaccines, and biologics.

Manufacturers face substantial challenges in meeting both national and international regulatory standards, which often include stringent testing protocols, sterilization processes, and packaging materials that can withstand temperature fluctuations and other environmental factors. Ensuring compliance with these regulations demands significant investments in quality control, research and development (R&D), and technology upgrades. For small and medium-sized vial manufacturers, the cost and complexity of adhering to these standards can be prohibitive, hindering their ability to scale operations.

Moreover, compliance with international standards like those set by the U.S. FDA or European Medicines Agency (EMA) is often necessary for manufacturers targeting global markets, adding another layer of complexity and cost. As India’s pharmaceutical exports grow, the pressure to meet these international standards becomes even more pronounced, limiting the growth potential for some domestic vial manufacturers. The ongoing need for continuous regulatory updates and compliance can slow down market agility, presenting a barrier to market expansion.

Raw Material Shortages and Price Volatility

The production of vials, especially glass vials, is highly dependent on the availability of raw materials such as borosilicate glass, rubber stoppers, and aluminum seals. India’s vials market is heavily influenced by the fluctuations in the prices and availability of these critical materials, many of which are imported. Disruptions in the global supply chain, such as those caused by geopolitical tensions, trade restrictions, or natural disasters, can lead to raw material shortages, price hikes, and delays in production.

For instance, borosilicate glass, which is the preferred material for pharmaceutical vials due to its resistance to chemical reactions and heat, is in limited supply and subject to significant price volatility. Similarly, the rubber and aluminum components that form the closure systems of vials also face price instability due to global supply chain issues. These fluctuations in raw material prices impact the overall cost structure of vial manufacturing, making it difficult for manufacturers to maintain competitive pricing while ensuring quality. Smaller manufacturers with limited resources may struggle to absorb these costs, leading to reduced margins or even an inability to meet the growing demand for vials. In turn, this can restrict the ability of the Indian vials market to scale effectively, particularly as global demand for vaccines and biologics increases.

Key Market Trends

Growing Demand for Biologics and Specialty Drugs

Growing demand for biologics and specialty drugs is emerging as a major growth engine for India’s vials market because complex injectable therapies such as monoclonal antibodies, insulins, biosimilars, and GLP 1 products require highly reliable primary packaging that can preserve sterility, stability, and product integrity throughout storage and administration.

India is strengthening its role in this space through large biopharma players, with Biocon Biologics reporting consolidated FY25 revenue of Rs 9,017 crore and stating that four of its biosimilars each recorded sales of USD 200 million during the year, reflecting the scale at which biologics production is expanding from India for global markets. This rise in biologics output is directly increasing the need for specialized vials made from high quality borosilicate glass, since these products demand tight dimensional precision, low reactivity, and dependable packaging performance across cold chain and injectable use cases.

For instance, SCHOTT Glass India said its Jambusar facility in Gujarat is the company’s second largest pharmaceutical tubing production site globally and that its India operations now cater to all glass primary packaging needs of pharma, from tubing for vials and ampoules to syringes and cartridges, highlighting how packaging suppliers are scaling up in anticipation of stronger demand from biologics and specialty drug manufacturing in India. As biologics, biosimilars, and advanced injectable therapies gain wider acceptance in oncology, diabetes, immunology, and rare disease treatment, the need for high performance vials in India is set to rise in parallel with the country’s expanding biopharmaceutical footprint.

Technological Advancements in Packaging Solutions

The increasing sophistication of injectable drug delivery systems is another key trend that will significantly impact the future of the India vials market. Advances in vial packaging technology are leading to the development of smarter, more user-friendly, and more secure vial solutions. These innovations include pre-filled syringes, auto-injectors, and multi-dose vials that offer convenience, reduce the risk of contamination, and improve patient compliance.

Additionally, the growing adoption of anti-counterfeiting technologies in packaging is reshaping the vials market. Vials are now being equipped with tamper-evident seals, RFID tags, and other security features to protect against counterfeit drugs, which are a growing concern globally. The integration of digital technologies into vials, such as smart sensors that monitor temperature, humidity, or even the vial’s usage, is gaining traction. These "smart vials" offer real-time data, ensuring that drugs are stored and transported within the recommended conditions, which is critical for biologics and vaccines. As manufacturers strive to meet the needs of the evolving pharmaceutical industry, the demand for technologically advanced vials will increase, thereby driving market growth.

Segmental Insights

Application Insights

Based on the category of Application, the Small Molecules segment emerged as the dominant in the India Vials Market in 2024. The small molecules segment has historically been the largest contributor to the India vials market, accounting for a significant share of the overall demand for vials. Small molecules, typically made up of low molecular weight compounds, are used in a wide range of therapeutic areas, including antibiotics, pain management, cardiovascular diseases, and other chronic conditions. These drugs are primarily delivered via oral tablets and injectables, with injectable formulations requiring vials for storage and administration.

India's pharmaceutical sector, which is one of the largest in the world, is heavily focused on the production and export of generic small-molecule drugs. The country is a global leader in the production of affordable generic medications, which are primarily injectable forms, driving a substantial demand for vials in the domestic market. The small molecule market also benefits from its relatively stable growth trajectory, as these drugs remain the standard treatment option for many diseases. This has led to consistent demand for vials, with manufacturers scaling production to meet both domestic consumption and export needs. These factors are expected to drive the growth of this segment.

Download Free Sample Report

Regional Insights

West India emerged as the dominant in the India Vials Market in 2024, holding the largest market share in terms of value. West India, particularly Maharashtra, Gujarat, and Goa, is the dominant region in the Indian vials market. This region is a key hub for the country’s pharmaceutical industry, which has a direct impact on the demand for vials used in drug storage, packaging, and administration.

West India is home to many pharmaceutical manufacturers, including both multinational corporations (MNCs) and domestic companies. Cities like Mumbai (Maharashtra) and Ahmedabad (Gujarat) are well-established as centers for pharmaceutical production, including the manufacturing of injectable drugs, vaccines, and biologics all of which require vials for packaging. The presence of key pharmaceutical players in these regions drives high demand for vials, particularly for small molecules, biologics, and vaccines. West India also plays a pivotal role in India’s pharmaceutical export sector.

The region is strategically located near major ports, such as Mumbai Port and Mundra Port, facilitating the export of pharmaceutical products and vials to international markets. As a result, the demand for vials in the region is not only driven by domestic consumption but also by the need to cater to global markets. West India boasts a well-developed infrastructure that supports both pharmaceutical manufacturing and packaging. The region’s advanced research and development (R&D) facilities, as well as its focus on technological innovations in packaging, also contribute to the rising demand for vials with specialized features, such as pre-filled syringes and multi-dose vials.

Recent Developments

• In February 2026, Glenmark announced that it would launch Sodium Phosphates Injection USP in single-dose vials in April 2026 through its U.S. business, representing another recent vial-format product development from an India-linked company.
• In October 2024, In response to the rising incidents of counterfeit medicines, particularly in the cancer treatment sector, anti-cancer drug vials and strips may soon be mandated to include QR codes and track-and-trace systems. This move aims to enhance the traceability and authenticity of these critical medications, helping to combat the growing threat of fake drugs in the market. The introduction of such technology is expected to bolster the security of drug distribution, ensuring that patients receive legitimate treatments while enabling regulatory bodies to monitor the supply chain more effectively.
• In March 2024, Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the operational launch of its newly upgraded biologics facility (Unit 3) in Bangalore, India. The facility was set to support clinical and commercial supply for U.S. and European clients in the latter half of 2024. The facility’s drug substance capacity included two production suites, each equipped with five 2KL single-use bioreactors, totaling a capacity of 20KL. Additionally, the facility featured two high-speed vial filling lines, capable of producing up to one million vials per day, with fill volumes ranging from one to 100mL. Beyond production capacity, the site housed a development suite for the clinical supply of drug substances, which included a 500L single-use bioreactor. Syngene officials stated that further expansion plans were in place, including the addition of two vial filling isolator lines with capacities of 600 vials/minute and 100 vials/minute, respectively, as well as an expansion into perfusion cell culture processing for drug substance production.

Key Market Players

• Amcor Group
• Corning Incorporated
• Gerresheimer AG
• KISHORE GROUP
• Nipro Medical India Pvt. Ltd
• SCHOTT Glass India Pvt. Ltd.
• SGD Pharma
• MITSUBISHI GAS CHEMICAL COMPANY, INC

Report Scope:

In this report, the India Vials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Vials Market, By Preparation:

o   Ready to use (RTU)

o   Ready to sterilize (RTS)

• India Vials Market, By Application:

o   Small molecules

o   Biologics

o   Diagnostics

• India Vials Market, By Material:

o   Glass

o   Polymer

o   Hybrid

• India Vials Market, By End User:

o   Hospitals & clinics

o   Pharma & biotech companies

o   Contract development and manufacturing organizations (CDMOs)

o   Diagnostic laboratories

o   Other

• India Vials Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Vials Market.

Available Customizations:

 India Vials market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).